News

Net profit of Akums Drugs & Pharmaceuticals rose 57.55% to Rs 100.01 crore in the quarter ended June 2026 as against Rs 63.48 crore during the previous quarter ended June 2025. Sales rose 13.93% to Rs 1166.63 crore in the quarter ended June 2026 as against Rs 1024.03 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales1166.631024.03 14 OPM %14.9712.59 - PBDT180.30132.57 36 PBT139.2495.65 46 NP100.0163.48 58 Powered by Capital Market - Live News

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 August 2026.

Akums Drugs & Pharmaceuticals announced that all manufacturing operations at the affected sites of the Company and its Subsidiaries, situated in the state of Uttarakhand, have been successfully resumed at 100% operations capacity with effect from 18 May 2026. The partial disruption in production at Haridwar sites lasted for four days which resulted in delayed supply of approx. Rs 20 crore. 

Akums Drugs & Pharmaceuticals announced that certain manufacturing sites at Haridwar have been impacted due to labour unrest at SIDCUL industrial area in Haridwar on 14 May 2026. The unrest has resulted in temporarily disruption of operations and active measures are being taken to normalize the operations.

Akums Drugs & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the special dividend of Rs 2 per equity Share (i.e. 100%) , subject to the approval of the shareholders.